The addition of Rituximab (R) to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL):: Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG).

被引：0
|
作者：
Hiddemann, W [1 ]
Unterhalt, M [1 ]
Dreyling, M [1 ]
Hossfeld, DK [1 ]
Lengfelder, E [1 ]
Metzner, B [1 ]
Pfreundschuh, M [1 ]
Kneba, M [1 ]
Fricke, HJ [1 ]
Böck, HP [1 ]
Schmitz, N [1 ]
Koch, P [1 ]
Fuchs, R [1 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 3, GLSG, D-8000 Munich, Germany
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
339
引用
收藏
页码：92A / 92A
页数：1
相关论文
共 50 条
  • [41] Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas -: results of a randomized comparison by the German Low-Grade Lymphoma Study Group
    Nickenig, C.
    Dreyling, M.
    Hoster, E.
    Ludwig, W. -D.
    Doerken, B.
    Freund, M.
    Huber, C.
    Ganser, A.
    Truemper, L.
    Forstpointner, R.
    Unterhalt, M.
    Hiddemann, W.
    ANNALS OF ONCOLOGY, 2007, 18 (01) : 136 - 142
  • [42] Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas - Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group
    Nickenig, Christina
    Dreyling, Martin
    Hoster, Eva
    Pfreundschuh, Michael
    Trumper, Lorenz
    Reiser, Marcel
    Wandt, Hannes
    Lengfelder, Eva
    Unterhalt, Michael
    Hiddemann, Wolfgang
    CANCER, 2006, 107 (05) : 1014 - 1022
  • [43] Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade lymphoma Study Group
    Determann, Olaf
    Hoster, Eva
    Ott, German
    Bernd, Heinz Wolfram
    Loddenkemper, Christoph
    Hansmann, Martin Leo
    Barth, Thomas E. F.
    Unterhalt, Michael
    Hiddemann, Wolfgang
    Dreyling, Martin
    Klapper, Wolfram
    BLOOD, 2008, 111 (04) : 2385 - 2387
  • [44] Evaluation of myeloablative therapy followed by autologous stem cell transplantation in first remission in patients with advanced stage follicular lymphoma after initial combined immuno-chemotherapy (R-CHOP) and conventional chemotherapy (CHOP): Analysis of 540 patients treated in prospective randomized trials of the German low grade lymphoma study group (GLSG)
    Buske, C.
    Dreyling, M. H.
    Hoster, E.
    Unterhalt, M.
    Hiddemann, W.
    ANNALS OF ONCOLOGY, 2008, 19 : 91 - 91
  • [45] Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group
    Raty, Riikka
    Honkanen, Tuomo
    Jantunen, Esa
    Jyrkkio, Sirkku
    Karjalainen-Lindsberg, Marja-Liisa
    Kuittinen, Outi
    Lehto, Minna
    Mikkola, Maija
    Poikonen, Eira
    Rauhala, Auvo
    Rimpilainen, Johanna
    Rasanen, Anu
    Siitonen, Sanna
    Suominen, Merja
    Vapaatalo, Mirja
    Elonen, Erkki
    BLOOD, 2014, 124 (21)
  • [46] Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lyphoma After Initial Immuno-Chemotherapy (R-CHOP) Or Chemotherapy Alone: Analysis Of 940 Patients Treated In Prospective Randomized Trials Of The German Low Grade Lymphoma Study Group (GLSG)
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    Metzner, Bernd
    Pfreundschuh, Michael
    Wilhelm, Martin
    Lengfelder, Eva
    Hess, Georg
    Hallek, Michael
    Schmitz, Norbert
    Pott, Christiane
    Fischer, Thomas
    Forstpointner, Roswitha
    Hoster, Eva
    Unterhalt, Michael
    BLOOD, 2013, 122 (21)
  • [47] Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group
    Lenz, G
    Dreyling, M
    Schiegnitz, E
    Haferlach, T
    Hasford, J
    Unterhalt, M
    Hiddemann, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) : 4926 - 4933
  • [48] Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)
    Hiddemann, Wolfgang
    Buske, Christian
    Kneba, Michael
    Dreyling, Martin
    Schmitz, Norbert
    Lengfelder, Eva
    Schmits, Rudolf
    Reiser, Marcel
    Metzner, Bernd
    Unterhalt, Michael
    BLOOD, 2008, 112 (11) : 286 - 287
  • [49] Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group
    Kimby, Eva
    Ostenstad, Bjorn
    Brown, Peter de Nully
    Holte, Harald, Jr.
    Hagberg, Hans
    Erlanson, Martin
    Linden, Ola
    Nordstrom, Marie
    Sundstrom, Christer
    BLOOD, 2012, 120 (21)
  • [50] Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group
    Lenz, G
    Dreyling, M
    Schiegnitz, E
    Forstpointner, R
    Wandt, H
    Freund, M
    Hess, G
    Truemper, L
    Diehl, V
    Kropff, M
    Kneba, M
    Schmitz, N
    Metzner, B
    Pfirrmann, M
    Unterhalt, M
    Hiddemann, W
    BLOOD, 2004, 104 (09) : 2667 - 2674
12345